Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
Deloitte
Johnson and Johnson
Cerilliant
Farmers Insurance
Accenture
Cantor Fitzgerald
Argus Health

Generated: July 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,623,826

« Back to Dashboard

Which drugs does patent 8,623,826 protect, and when does it expire?

Patent 8,623,826 protects AKYNZEO and is included in one NDA.

This patent has fifty-four patent family members in thirty-seven countries.
Summary for Patent: 8,623,826
Title:Compositions and methods for treating centrally mediated nausea and vomiting
Abstract: Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.
Inventor(s): Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee: Helsinn Healthcare S.A. (Lugano/Pazallo, CH)
Application Number:13/077,462
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,623,826

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,623,826

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,951,969 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Try a Free Trial
9,271,975 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Try a Free Trial
9,186,357 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,623,826

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
San Marino T201400112 ➤ Try a Free Trial
Slovenia 2722045 ➤ Try a Free Trial
Slovenia 2361090 ➤ Try a Free Trial
Serbia 55206 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
McKinsey
US Army
Daiichi Sankyo
UBS
Boehringer Ingelheim
McKesson
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.